BerGenBio

Selective AXL inhibitors

Home  /  Investors

Investors

Yearly Reports

Annual Report 2021

BerGenBio (OSE:BGBIO) is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including immune evasive, drug resistant and metastatic cancers.

Our annual report

Corporate Presentation

Pareto Securities’ 13th Annual Healthcare Conference

7 September 2022

Read More

Share price

BerGenBio ASA

BGBIO (Norway: Oslo)

Share Price Chart

News

Latest News

BerGenBio Reports Third Quarter 2022 Financial Results and Provides Business Update

BerGenBio Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations

BERGENBIO ANNOUCES FIRST PATIENT RANDOMIZED IN BEMCENTINIB TRIAL IN EU-SOLIDACT PLATFORM FOR HOSPITALIZED COVID-19 PATIENTS

More News

Scientific Presentations

ASCO 2022, Bhalla et al.

6 June 2022

Read More

Annual Report 2021

BerGenBio (OSE:BGBIO) is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including immune evasive, drug resistant and metastatic cancers.

Our annual report

Events

Upcoming Events

BerGenBio ASA: Invitation to third quarter 2022 results webcast

  Annual General Meeting April 28th

  Q1 2022 Results May 24, 2022

BERGENBIO ASA: Invitation to THIRD quarter 2021 results

BERGENBIO ASA: Invitation to PRESENTATION OF SECOND quarter and HALF YEAR 2021 results

More Events

Subscribe to our newsletter

Please remember to confirm your email by clicking on the link provided in the subscription confirmation email. We will save your name and email address with the sole purpose of sending information regarding our latest news and events. By subscribing to BerGenBio’s newsletter you consent to our Privacy Policy and Terms of Use.